Last $7.33 USD
Change Today -0.11 / -1.48%
Volume 205.0K
POZN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

pozen inc (POZN) Snapshot

Open
$7.41
Previous Close
$7.44
Day High
$7.50
Day Low
$7.31
52 Week High
04/25/14 - $9.73
52 Week Low
07/31/14 - $5.96
Market Cap
235.1M
Average Volume 10 Days
200.0K
EPS TTM
$0.34
Shares Outstanding
32.1M
EX-Date
12/31/13
P/E TM
21.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for POZEN INC (POZN)

Related News

No related news articles were found.

pozen inc (POZN) Related Businessweek News

No Related Businessweek News Found

pozen inc (POZN) Details

POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its primary PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed clinical development in the United States. The company’s products also include Treximet for acute treatment of migraine attacks with or without aura in adults; and VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and Sanofi US for the commercialization of PA product candidates, as well as with AstraZeneca AB. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

16 Employees
Last Reported Date: 03/6/14
Founded in 1996

pozen inc (POZN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $591.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $353.1K
Chief Medical Officer
Total Annual Compensation: $372.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $339.8K
Compensation as of Fiscal Year 2013.

pozen inc (POZN) Key Developments

POZEN Mulls Acquisitions

POZEN Inc. (NASDAQ:POZN) will sell up to 8 million shares of its common stock in one or more offerings and intends to use proceeds for product acquisitions and/or potential acquisitions of complementary businesses.

POZEN Inc.(NasdaqGS:POZN) added to NASDAQ Biotechnology Index

POZEN Inc. will be added to the NASDAQ Biotechnology Index.

Pozen Inc.'s Investigational Drug Candidates Yosprala™ 81/40 and 325/40 Receives Second Complete Response Letter from the U.S. Food and Drug Administration

POZEN Inc. announced that their investigational drug candidates YOSPRALA™ 81/40 and 325/40 (aspirin /omeprazole delayed release tablets) have received a second complete response letter (CRL) from the U.S. Food and Drug Administration (FDA). A CRL is issued by the FDA when the review of the file is completed and questions remain that preclude the approval of the new drug application (NDA) in its current form. In this CRL, the FDA used identical wording to that of the first CRL, which was that during an inspection of the foreign manufacturing facility of an active ingredient supplier on April 25, 2014, a FDA field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved. There were no clinical or safety deficiencies noted with respect to either YOSPRALA 81/40 or YOSPRALA 325/40 and no other deficiencies were noted in the CRL. Final agreement on the draft product labeling is also pending. The supplier responded to FDA’s deficiencies in May, 2014 with a complete plan of action to correct all of the deficiencies noted. Since that time, the supplier has provided updates to the FDA on their progress on the action plan. During interactions with the supplier, POZEN confirmed that there has been no new inspection of the facility from the compliance division at the FDA since last April, and that the facility has received no communication or comment from the compliance division at the FDA with respect to the supplier’s action plan and progress on the plan to address the deficiencies, other than informing the supplier that the matter is under review and that the division has many competing priorities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POZN:US $7.33 USD -0.11

POZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,470 GBp +4.50
Endo International PLC $85.60 USD +0.36
GlaxoSmithKline PLC 1,542 GBp -12.50
Merck & Co Inc $58.54 USD -0.42
Sunesis Pharmaceuticals Inc $2.22 USD 0.00
View Industry Companies
 

Industry Analysis

POZN

Industry Average

Valuation POZN Industry Range
Price/Earnings 22.5x
Price/Sales 8.5x
Price/Book 6.2x
Price/Cash Flow 22.4x
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POZEN INC, please visit www.pozen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.